Biogen expects about $2 million Q3 2025 acquired R&D charge, a $0.01 per share hit
Biogen said its preliminary third-quarter 2025 GAAP and non-GAAP results will include about $2 million pre-tax of acquired in-process research and development, upfront and milestone expense. The charge is expected to reduce diluted earnings per share by about $0.01, and the quarter's results have not been finalized.
Key points
- Estimated pre-tax acquired IPR&D, upfront and milestone expense: about $2 million for Q3 2025
- Expected impact on GAAP and non-GAAP diluted EPS: about ($0.01) per share
- Quarter ended September 30, 2025 results are unaudited, not finalized, and could differ from these estimates
- Biogen does not forecast this expense category due to the uncertain timing and size of such deals
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.